Sponsor

RVL Pharmaceuticals, Inc.

Clinical research sponsor

Published trials6
Recruiting shown0
Roles1
SourceClinicalTrials.gov

Clinical trials

6 shown
A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple SclerosisNCT05179577 · lead sponsor · 2027-01-01
NOT_YET_RECRUITING
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MSNCT03319732 · lead sponsor · 2018-04-03
COMPLETED
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MSNCT03290131 · lead sponsor · 2018-01-28
COMPLETED
To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MSNCT02869425 · lead sponsor · 2016-07-01
WITHDRAWN
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With SpasticityNCT01844232 · lead sponsor · 2013-04-01
COMPLETED
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple SclerosisNCT01743651 · lead sponsor · 2012-11-01
COMPLETED

Sponsor roles

lead sponsor6

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.